Jeffrey Rosenfeld PhD

Dr. Jeffrey Rosenfeld PhD

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2019 in Neurology
Verified
Journal Article
Open access
PDF file
LBLudo Van Den Bosch
Ludo Van Den Bosch
ESEric Sorenson
Eric Sorenson
GGGary Gronseth
Gary Gronseth
EMEric A. Macklin
Eric A. Macklin
JAJinsy Andrews
Jinsy Andrews
FGfor the Airlie House ALS Clinical Trials Guidelines Group
for the Airlie House ALS Clinical Trials Guidelines Group
Objective To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS). Methods A consensus committee comprising 140 key members of the international ALS community (ALS researchers, clinicians, patient representatives, research funding representatives, industry, and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies; (2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical trial phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8 sections, committee members generated a draft set of guidelines based on a “background” of developing a (pre)clinical question and a “rationale” outlining the evidence and expert opinion. Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified Delphi process was used to develop draft consensus research guidelines, which were subsequently reviewed and modified based on comments from the public. Statistical experts drafted a separate document of statistical considerations (section 9). Results In this report, we summarize 112 guidelines and their associated backgrounds and rationales. The full list of guidelines, the statistical considerations, and a glossary of terms can be found in data available from Dryad (appendices e-3–e-5, doi.org/10.5061/dryad.32q9q5d). The authors prioritized 15 guidelines with the greatest potential to improve ALS clinical research. Conclusion The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to improve clinical trial design and accelerate the development of effective treatments for patients with ALS.

1 March 2008 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
RHRichelle A. Hemendinger
Richelle A. Hemendinger
EAEdward J. Armstrong
Edward J. Armstrong
RPRafal Persinski
Rafal Persinski
JTJulianne Todd
Julianne Todd
JMJean-Luc C. Mougeot
Jean-Luc C. Mougeot
JPJeffrey Rosenfeld PhD
Jeffrey Rosenfeld PhD

1 January 2018 in touchREVIEWS in Neurology
Verified
Journal Article
Open access
SBSaid R Beydoun
Said R Beydoun
JPJeffrey Rosenfeld PhD
Jeffrey Rosenfeld PhD
Edaravone significantly slows progression of amyotrophic lateral sclerosis (ALS), and is the first therapy to receive approval by the Food and Drug Administration (FDA) for the disease in 22 years. Approval of edaravone has marked a new chapter in pharmaceutical development since the key trial included a novel strategic clinical design involving cohort enrichment. In addition, approval was based on clinical trials that had a relatively small patient number and were performed outside of the US. Edaravone was developed through a series of clinical trials in Japan where it was determined that a well-defined subgroup of patients was required to reveal a treatment effect within the study period. Amyotrophic lateral sclerosis is associated with wide-ranging disease heterogeneity (both within the spectrum of ALS phenotypes as well as in the rate of progression). The patient cohort enrichment strategy aimed to address this heterogeneity and should now be considered as a viable, and perhaps preferred, trial design for future studies. Future research incorporating relevant biomarkers may help to better elucidate edaravone’s mechanism of action, pharmacodynamics, and subsequently ALS phenotypes that may preferentially benefit from treatment. In this review, we discuss the edaravone clinical development program, outline the strategic clinical trial design, and highlight important lessons for future trials.

6 March 2020 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
PDF file
YWYan Chen Wongworawat
Yan Chen Wongworawat
YLYin Allison Liu
Yin Allison Liu
RRRavi Raghavan
Ravi Raghavan
CWCharles L White
Charles L White
RDRobin Dietz
Robin Dietz
JPJeffrey Rosenfeld PhD
Jeffrey Rosenfeld PhD
A 29-year-old man presented with rapidly progressive severe neck weakness, asymmetrical bilateral upper extremity weakness, bulbar dysfunction, profound muscle wasting, and weight loss. Within 1 year, his speech became unintelligible, he became gastrostomy- and tracheostomy/ventilator-dependent, and wheelchair bound. Electrophysiology suggested motor neuron disease. Whole exome sequencing revealed a heterozygous pathogenic variant in the fused in sarcoma gene (FUS), c.1574C>T,p. R525L, consistent with autosomal dominant amyotrophic lateral sclerosis. Autopsy revealed extensive denervation atrophy of skeletal musculature. Surprisingly, there was only minimal patchy depletion of motor neurons within the cervico-thoracic spinal cord anterior horn cells, and the tracts were largely preserved. TDP-43 inclusions were absent. Abnormal expression of FUS mutation product (cytoplasmic inclusions) was demonstrated by immunohistochemistry within anterior horn motor neurons. The most prominent finding was a disparity between profound neck weakness and relatively low-grade anterior horn cell loss or tract degeneration in the cervico-thoracic cord.

1 November 2018 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
PDF file
JPJeffrey Rosenfeld PhD
Jeffrey Rosenfeld PhD
Amyotrophic lateral sclerosis (ALS) is a progressive disorder characterized by degeneration of motor neurons in the brain and spinal cord. The onset of the disease can include clinical signs of upper (brain) motor neuron decline or more typically lower (spinal cord) motor neuron degeneration. Anatomically, patients may present with clinical signs affecting only the bulbar region (speech, swallowing, breathing), only the limbs, or both areas simultaneously. The pace of motor neuron degeneration can be accelerated, with death ensuing from paralysis and/or respiratory arrest within 3 years, or quite indolent, with patients surviving more than 10 years. The diagnosis is largely based on clinical examination with electromyography used to confirm lower motor neuron involvement and rule out other similar presentations confounding the diagnosis.1 x 1 Brown, R.H. Jr. and Al-Chalabi, A. Amyotrophic lateral sclerosis [letter]. N Engl J Med. 2017; 377: 1602 Crossref | Scopus (0) | Google Scholar See all References , 2 x 2 Rosenfeld, J. and Strong, M.J. Challenges in the understanding and treatment of amyotrophic lateral sclerosis/motor neuron disease. Neurotherapeutics. 2015; 12: 317–325 Crossref | Scopus (5) | Google Scholar See all References

1 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SYShao Feng Yu
Shao Feng Yu
MMMaya Michon
Maya Michon
ALAnuradha F. Lingappa
Anuradha F. Lingappa
KPKumar Paulvannan
Kumar Paulvannan
DSDennis Solas
Dennis Solas
Vishwanath LingappaVishwanath Lingappa
Vishwanath Lingappa
Assembly modulators are a new class of allosteric site-targeted therapeutic small molecules, some of which are effective at restoring nuclear localization of TDP-43 in ALS cellular models, and which display efficacy in a variety of ALS animal models. These compounds have been shown to bind selectively to a small subset of protein disulfide isomerase (PDI), a protein implicated in ALS pathophysiology. The targeted subset of PDI is found within a novel, transient and energy-dependent multi-protein complex that includes other important members of the ALS interactome, such as TDP-43, RanGTPase, and selective autophagy receptor p62/SQSTM1. We demonstrate here that a similar multi-protein complex drug target is present in PBMCs as isolated by energy-dependent drug resin affinity chromatography (eDRAC) and characterized by mass spectrometry and by Western blot (WB). Signature alterations in the composition of the multi-protein complex in PBMCs from ALS patients compared to PBMCs from healthy individuals were identified by WB of eDRAC bound proteins, thereby extending earlier literature suggesting PBMC dysfunction in ALS. Changes in the PBMC drug target in ALS patients compared to healthy individuals include diminished p62/SQSTM1 and appearance of a 17kDa post-translationally modified form of RanGTPase. These changes are not readily apparent from analysis of whole cell extracts, as the individual protein components within the drug target multi-protein complex comprise only small percentages of the total of those component proteins in the extract. Furthermore, whole blood from ALS patients shows a distinctive degradation of total RanGTPase not observed in blood from healthy individuals. This degradation appears to be rescued by treatment of whole blood from ALS patients for 72 hrs with ALS-active assembly modulator small molecules. Our findings are consistent with the hypothesis that ALS is fundamentally a disorder of homeostasis that can be detected early, prior to disability, in blood by the methods described, and restored to the healthy state by assembly modulator drug treatment.